Castle Biosciences (NASDAQ:CSTL) Insider Sells $507,356.10 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 17,310 shares of the stock in a transaction on Friday, July 31st. The stock was sold at an average price of $29.31, for a total value of $507,356.10. Following the completion of the transaction, the insider owned 80,725 shares of the company’s stock, valued at $2,366,049.75. The trade was a 17.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

Shares of NASDAQ CSTL opened at $30.47 on Friday. The firm has a market capitalization of $930.86 million, a P/E ratio of -46.17 and a beta of 0.98. Castle Biosciences, Inc. has a one year low of $17.72 and a one year high of $44.28. The company’s fifty day moving average is $23.55 and its two-hundred day moving average is $26.16. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.85 and a current ratio of 6.04.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.34. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. The business had revenue of $99.86 million during the quarter, compared to the consensus estimate of $86.23 million. Analysts forecast that Castle Biosciences, Inc. will post -1.29 EPS for the current fiscal year.

Castle Biosciences News Roundup

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: BTIG raised its price target to $44 from $40 and maintained a “buy” rating. The higher target reflects confidence in Castle Biosciences’ molecular-diagnostics growth outlook and suggests meaningful upside from recent trading levels. BTIG raises Castle Biosciences price target
• Positive Sentiment: Castle Biosciences’ latest quarterly results significantly exceeded expectations. Revenue reached $99.86 million versus the $86.23 million consensus estimate, while the per-share loss was $0.07 compared with the expected $0.41 loss. The company remains unprofitable, but the revenue growth and narrower loss reinforce the improving operating outlook.
• Neutral Sentiment: Institutional investors and hedge funds continue to hold approximately 92.6% of Castle Biosciences’ outstanding shares. Recent position increases by firms including AQR Capital Management, Amundi and Legal & General may provide some institutional support, although these ownership changes are not necessarily a near-term catalyst.
• Negative Sentiment: Several insiders reported sizable stock sales. Derek J. Maetzold sold 39,016 shares for roughly $1.21 million in transactions on August 4–5, while COO Kristen Oelschlager sold 8,586 shares for about $256,000. Tobin W. Juvenal also disclosed a 1,730-share sale worth approximately $49,000. The sales reduce insider ownership and could weigh on sentiment after the stock’s recent advance, although the transactions were executed under pre-arranged Rule 10b5-1 plans, making them a less definitive bearish signal. Castle Biosciences insider sales filing

Institutional Trading of Castle Biosciences

Several large investors have recently modified their holdings of the business. Global Retirement Partners LLC purchased a new stake in Castle Biosciences in the 2nd quarter valued at approximately $26,000. Federated Hermes Inc. purchased a new position in Castle Biosciences during the fourth quarter worth $26,000. Kemnay Advisory Services Inc. purchased a new position in Castle Biosciences during the fourth quarter worth $35,000. Jones Financial Companies Lllp raised its holdings in shares of Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after acquiring an additional 2,648 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Castle Biosciences by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock worth $55,000 after acquiring an additional 297 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Roth Capital assumed coverage on shares of Castle Biosciences in a research report on Wednesday, June 24th. They set a “buy” rating and a $40.00 price target for the company. Robert W. Baird set a $36.00 price objective on Castle Biosciences in a research note on Friday, July 31st. KeyCorp set a $35.00 price objective on Castle Biosciences in a report on Friday, May 29th. Wall Street Zen upgraded Castle Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Canaccord Genuity Group lowered their target price on Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $42.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.